HCM HUTCHMED (China) Limited: Market Capitalization to Book Value Ratio

Official company branding of Hutchison MediPharma (HCM)

Developing new cancer drugs requires colossal research expenditures and navigating stringent FDA oversight. The price action of HUTCHMED (China) Limited (HCM) at the 1.91 level illustrates the trajectory of a company that delegates manufacturing and marketing to external contractors to concentrate on therapy. Meanwhile, the Hong Kong-based business is overcoming the complexities of the US-China trade conflict by establishing sophisticated legal structures for expansion.

HUTCHMED Corp (HCM): Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

HCM (Hutchison MediPharma): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price HUTCHMED (China) Limited|HCM - Analyst Target Range
- market capitalization data:
Market Capitalization HUTCHMED Ltd|HCM - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share HUTCHMED|HCM - Accounting Capitalization|Market Capitalization to Book Value Ratio hutch-med.com|HCM - Company Assets
- debt and liquidity data:
Debt to Equity HUTCHMED (China) Limited|HCM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital HUTCHMED Ltd|HCM - Company Aggregate Debts|Debt to Book Capitalization Ratio HUTCHMED Ltd|HCM - Company Long-Term Debt|Company Current Liabilities HUTCHMED
Fundamental valuation:HUTCHMED (China) Limited
Original product of Hutchison MediPharma

To assess the credit quality of HUTCHMED (China) Limited (HCM), the analyst compares the business's market value with its net assets, which allows for the determination of the growth premium through the company's current P/B ratio. HUTCHMED (China) Limited (HCM) strategic alliances in oncology and clinical trial synergies create intangible value that often exceeds book value, reflecting the commercialization potential of new drugs.

Main competitors

Market Capitalization to Book Value Ratio INCY (Incyte Corporation)|nuvationbio.com (NUVB) - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio DAWN (Day One Biopharmaceuticals)|Market-to-Book Ratio MNPR|Market Value to Book Value Ratio Inhibrx Biosciences Inc INBX|Capitalization to Book Value Ratio i-mabbiopharma.com (IMAB)|FENC: Market Capitalization to Book Value Ratio|Heron - Market-to-Book Ratio|Market Value to Book Value Ratio Nuvectis Pharma (NVCT)|CHRS - Market Value to Book Value|CRBP: Market Capitalization to Book Value Ratio|CRDF (Cardiff Oncology) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio BeyondSpring Inc.|Market Value to Book Value Ratio BioAtla Corp (BCAB)|Lixte Biotechnology Holdings, Inc. (LIXT) - Market Cap to Net Assets Ratio|Market Value to Book Value CTXR (citiuspharma.com)|CLRB: Market Value to Book Value Ratio|BioLineRx Corporation - Market-to-Book Ratio|Can-Fite BioPharma (CANF) - Market Value to Book Value Ratio|APRE - Capitalization to Book Value Ratio|KZIA (kaziatherapeutics.com) - Market Capitalization to Book Value Ratio|SLXN (Silexion Therapeutics) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio NCNA (NuCana PLC)|Market-to-Book Ratio CMRX|Market Value to Book Value Ratio Cyclacel Pharmaceuticals (CYCC)|Market Value to Book Value Ratio GTHX (g1therapeutics.com)|KRON: Market Value to Book Value Ratio|Market-to-Book Ratio Kintara Therapeutics Inc KTRA|Market Capitalization to Book Value Ratio ONCT|Portage Biotech Corp (PRTG) - Market Value to Equity Ratio